Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07131085) titled 'QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Anhui Provincial Hospital
Condition:
MDS
AML
Intervention:
Drug: Allogeneic TCR-enhanced ?d T cell(QH101)
Drug: Fludarabine (FLU)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 15, 2025
Target Sample Size: 9
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07131085
D...